Showing results (1551-1560 of 1,729) with videos related to
Sort By:
Pageof 173
Physical Review Letters|September 26, 2025
Picosecond Expansion in LaAlO_{3} Resonantly Driven by Infrared-Active PhononsJakob Gollwitzer, Jeffrey Z Kaaret, Y Eren Suyolcu, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 13, 2025
Experiences and expectations of advance directives in gynecological cancer patients (the NOGGO-expression X study)Melisa Guelhan Inci, Ebru Ilter, Eva Roser, et al.Bulletin Du Cancer|March 26, 2023
Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancerPhilipp Harter, Gerhard Bogner, Luis Chiva, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 7, 2024
GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancerRachel Grisham, Bradley J Monk, Els Van Nieuwenhuysen, et al.BMC Cancer|September 19, 2023
The TRIPLEX study: use of patient-derived tumor organoids as an innovative tool for precision medicine in triple-negative breast cancerJordane Divoux, Romane Florent, Margaux Jacobs, et al.Journal of Medical Genetics|December 4, 2020
Sensitivity and specificity of loss of heterozygosity analysis for the classification of rare germline variants in BRCA1/2: results of the observational AGO-TR1 study (NCT02222883)Jan Hauke, Philipp Harter, Corinna Ernst, et al.International Journal of Cancer|August 6, 2019
Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancerIsabelle Ray-Coquard, David Cibula, Mansoor R Mirza, et al.Gynecologic Oncology|September 15, 2019
Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancerI Vergote, A du Bois, A Floquet, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 21, 2015
Pazopanib Maintenance Therapy in East Asian Women With Advanced Epithelial Ovarian Cancer: Results From AGO-OVAR16 and an East Asian StudyJae-Weon Kim, Sven Mahner, Ling-Ying Wu, et al.European Journal of Cancer (Oxford, England : 1990)|May 28, 2023
PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trialLiselore Loverix, Ignace Vergote, Pieter Busschaert, et al.Pageof 173